mobile  Test Directory

DOXEPIN AND METABOLITE

Test Code
DOXMP
 
This test is a lab developed test. For further information, see the Compliance Remarks section below.
Synonyms
Adapin; Nordoxepin; Prudoxin; Sinequan; Zonalon
SPECIMEN REQUIREMENTS
Container Type
Red top tube (plain)
Supply Item Number
1372
Specimen Type
Serum
Preferred Volume
0.5 mL
Emergency Minimum Volume
0.2 mL
Patient Prep
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Collection Procedure
Optimal time to collect sample: Draw 10-14 hours post-dose. If a divided dose is given, draw before morning dose.
Specimen Processing
Blood samples should be collected by venipuncture in a plain red top and serum samples must be allowed to clot naturally at room temperature. Separate serum from cells within 4 hours and place in separate polypropylene (not polystyrene) tube.
Store and Transport
Refrigerated
Required Patient Info
Date and time of dose and draw
Stability
Room Temp 5 days  Refrigerated 1 week  Frozen (-20 °C) 1 month  Frozen (-70 °C) 1 year  
Unacceptable Condition
DO NOT use gel separator tubes (Corvac®, SST or equivalent) for the collection of blood samples for this test.
Reference Laboratory
PAML
Reference Lab Test Code
LCA code 911179
CPT Codes
80335, (HCPCS G0480)
Interface Order Code
80166.Z3
Billing Code
DOXMP
Test Schedule
Mon, Wed, Fri
Turnaround Time
1-3 days
Method
Tandem Mass Spectrometry
Reference Ranges
TitleDescriptorRangesUnits
DoxepinNot establishedng/mL
NordoxepinNot establishedng/mL
Total (Doxepin + Nordoxepin)Therapeutic50-150ng/mL
Toxic> 150ng/mL
Compliance Remarks
This test was developed and its performance characteristics determined by PAML. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. PAML is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
Notes
Plasma concentrations vary widely among patients. The therapeutic range listed relates to the antidepressant characteristics of the drug. A therapeutic range for treating obsessive compulsive disorder is not well defined.

Interface Codes
typeorder codetest descriptionresult coderesult descriptionunitsdecimal placesloinc code
o80166.Z3Doxepin and Metabolite
r80166.Z3Doxepin and Metabolite80166.Z1Doxepinng/mL 3579-0
r80166.Z3Doxepin and Metabolite80166.Z2Doxepine/Nordoxepine Totalng/mL 3582-4
r80166.Z3Doxepin and Metabolite80299.Z71Nordoxepinng/mL 3862-0

v1.0|1101|3|1|0


Questions/Comments